E-mail: lling@51chemall.com
Contact Us
Wuhan Lihe New Chemical Materials Co.,Ltd
Add: Room 1801, Building B, Wuhan University Of Technology Entrepreneur Incubator, Hongshan, Wuhan, Hubei, China
Home > About Us > Our History
Our History

Wuhan Lihe Chemical New Material Co., Ltd. is the first high-tech enterprise specialized in chiral drug intermediates and API research and development and industrialization in Hubei Province. It established the largest professional chiral drug in Central China in the “China Optics Valley” biological industrial park. R & D experimental base,which has advanced chiral drug research and development equipment, a world-class team of technical experts, and an extremely rich experience in drug development and industrialization. The company has completed the industrialization process of more than twenty kinds of chiral drugs such as esomeprazole sodium, dexlansoprazole, and aprepitant.  The company has established close cooperative relations with more than 400 pharmaceutical companies at home and abroad including Shiyao Group, Guangyao Pharmaceutical Group, Yangzijiang Pharmaceutical, Renfu Group, etc.



The company has obtained the fourth batch of road map plans for science and technology SME in Hubei Province, the seventh batch of Donghu Development Zone, the ninth batch of “3551 Optical Valley Talents” plan, and the National Science and Technology SME Technology Innovation Fund Investment Protection Plan, Wuhan Science and Technology Type SME Innovation Fund and many other government support programs.



The company has ac cumulatively invested R&D funds of more than 15 million yuan, owns a modern medicine research and development test base of nearly 1,000 square meters, and jointly established the "transformation medicine and new drug R&D laboratory" with Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology. It has jointly established   Nanjing “Chiral Technology R&D Experimental Base” at the Nanjing Baijiahui Drug R&D Center with Jiangsu Xianshen Pharmaceutical Group, and signed “International Chiral Technology R&D Exchange Plan Agreement” with Australian Monash University to jointly cultivate high quality chiral technical professional research talents.


As of April 2018, the company's own funds has exceeded 50 million yuan. In March 2018, it completed A+ round of 50 million yuan in risk financing, providing a strong financial guarantee for the implementation and operation of the project.



Copyright © Wuhan Lihe New Chemical Materials Co.,Ltd All Rights Reserved.